RT Journal Article
SR Electronic
T1 Proteomics Uncovers Immunosuppression in COVID-19 Patients with Long Disease Course
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.14.20131078
DO 10.1101/2020.06.14.20131078
A1 Tang, Shaohua
A1 Sun, Rui
A1 Xiao, Qi
A1 Mao, Tingting
A1 Ge, Weigang
A1 Huang, Chongquan
A1 Luo, Meng
A1 Qian, Liujia
A1 Chen, Hao
A1 Zhang, Qiushi
A1 Li, Sainan
A1 Liu, Wei
A1 Li, Shufei
A1 Xu, Xueqin
A1 Li, Huanzheng
A1 Wu, Lianpeng
A1 Dai, Jianyi
A1 Gao, Huanhuan
A1 Li, Lu
A1 Lu, Tian
A1 Liang, Xiao
A1 Cai, Xue
A1 Ruan, Guan
A1 Liu, Kexin
A1 Xu, Fei
A1 Li, Yan
A1 Zhu, Yi
A1 Huang, Jianping
A1 Guo, Tiannan
YR 2020
UL http://medrxiv.org/content/early/2020/06/16/2020.06.14.20131078.abstract
AB Little is known regarding why a subset of COVID-19 patients exhibited prolonged positivity of SARS-CoV-2 infection. Here, we present a longitudinal sera proteomic resource for 37 COVID-19 patients over nine weeks, in which 2700 proteins were quantified with high quality. Remarkably, we found that during the first three weeks since disease onset, while clinical symptoms and outcome were indistinguishable, patients with prolonged disease course displayed characteristic immunological responses including enhanced Natural Killer (NK) cell-mediated innate immunity and regulatory T cell-mediated immunosuppression. We further showed that it is possible to predict the length of disease course using machine learning based on blood protein levels during the first three weeks. Validation in an independent cohort achieved an accuracy of 82%. In summary, this study presents a rich serum proteomic resource to understand host responses in COVID-19 patients and identifies characteristic Treg-mediated immunosuppression in LC patients, nominating new therapeutic target and diagnosis strategy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000031699Funding StatementThis work is supported by grants from Tencent Foundation (2020), National Natural Science Foundation of China (81972492, 21904107, 81672086), Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholars (LR19C050001), and Hangzhou Agriculture and Society Advancement Program (20190101A04).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the Ethical/Institutional Review Board of Wenzhou Central Hospital and Westlake University. Contents from patients were waived by the boardsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript or the supplementary material. The proteomics data are deposited in ProteomeXchange Consortium (https://www.iprox.org/). Project ID: IPX0002170000. https://www.iprox.org/